Nabla Engineering 60%, Marketing One Person—Surprising Split

The Round That Changes the Category

Nabla closed a $70 million Series C on June 17, 2025, Source 1's data shows. Microsoft's Nuance division responded with a migration guide targeting Nabla's installed base, "How to Switch from Nabla to DAX Copilot," framing the ambient scribe race as a contest between agentic execution and installed-base lock-in. HV Capital, Highland Europe, and Cathay Innovation led the round, bringing total funding to $120 million, Source P1 reported. All three firms have tracked the company since its founding by ex-Meta AI Research engineers. (Note: Nabla, the clinical AI assistant, is distinct from Nabla Bio, a separate U.S. entity developing protein therapeutics with a Takeda collaboration.)

Co-founders Alex LeBrun, Delphine Groll, and Martin Raison sold their first AI startup to Nuance and their second to Facebook. Before writing production code, they ran a digital clinic with 50 employed physicians to learn the workflow. That bottom-up origin still shapes capital deployment: 60 percent of the team is engineering; a single person handles marketing.

HV Capital partner Alexander Joel-Carbonell called the execution "extraordinary." Dr. Ed Lee, chief medical officer and former CIO of The Permanente Federation, sits on the leadership team alongside advisors Yann LeCun and Tony Fadell. The new capital accelerates product development toward an adaptive agentic platform, grows technical, clinical, and go-to-market teams, and funds strategic partnerships to expand into new care settings at national scale.

Capital to Headcount: Early Signals

Nabla's careers page lists open roles across sales and engineering, reflecting the dual mandate to commercialize the ambient scribe and build the agentic platform. The company states it is "growing faster than ever" following the Series C raise. Leadership reinforcement arrived with Priscilla Pennington joining as Vice President of Sales, bringing 15 years of experience from the Greater Tampa Bay Area, extending the U.S. footprint beyond New York. Her hire aligns with the Series C narrative of pursuing this strategy.

The company has not disclosed a total headcount target or hiring timeline beyond "faster than ever." The role mix, including partnership directors, a mid-market account executive, a growth marketing lead, and backend engineering, maps directly to the stated uses of proceeds.

The Agent Bet: Beyond Documentation

That commercial and infrastructure wave is building toward a product shift Nabla says the market already demands. The ambient scribe category Nabla helped define is barely two years old, yet the company's own blog post declares its first chapter closed: "Two years ago, every 'medical scribe' demo would get a standing ovation. Today, clinicians' expectations have dramatically increased. The days of 'one size fits all' and 'just copy-paste, it's not integrated' are over."

The new agentic platform centers on three agent types the company has committed to building with Series C capital. A Proactive Coding Agent will extend existing real-time ICD-10, HCC, and MCC support toward E/M coding guidance and compliance nudges. A Context-Aware Agent will move beyond patient summaries and pre-charting to initiate orders and execute EHR commands through an intuitive interface. A Custom Care Setting Agent will deploy capabilities tailored for nurses, with early expansion into inpatient environments and other frontline roles. Each agent leverages a domain-specific large language model refined over several years on clinically grounded data and an evaluation framework that includes human medical experts and non-LLM technologies, infrastructure the company says enables advanced customization without compromising accuracy.

The architectural bet is extensibility. Rather than shipping a monolithic product, Nabla exposes its core infrastructure — medical reasoning, encounter structuring, context awareness, clinical coding, agentic integrations, model monitoring and evaluation — so health systems can build their own agents on top. "Need a post-encounter agent built for your department that talks to three legacy tools and pulls labs from an API-less system? Included," the blog post reads. That posture reflects a recognition that Epic, Cerner, athenahealth, NextGen, Greenway and dozens of other EHRs — some still running on COBOL without modern APIs — require bespoke wiring no single vendor can hard-code.

Alex Lebrun, Nabla's co-founder and CEO, put the shift in workflow terms: "We're going even deeper into clinical workflows while continuing to offer a highly customizable assistant that works across specialties." The press release adds that the platform unifies ambient listening, dictation, coding, and command capabilities into a single extensible agentic platform, aiming toward a proactive assistant that "intuitively streamlines existing workflows." The company also joined the Coalition for Health AI and issued a CHAI Applied Model Card to surface model behavior, a governance move that signals anticipation of regulatory scrutiny as agentic actions move closer to clinical decision-making. The journey, as Lebrun notes, is "1% done."

Where the Rubber Meets the EHR

As of June 2025, Nabla reports more than 85,000 clinicians active on its platform across 130-plus healthcare organizations, processing 20 million annual encounters and over 30 billion tokens each month. Live annual recurring revenue grew fivefold in the six months preceding the funding announcement, Source 2 found (recognized revenue, not contracted bookings). The footprint spans rural hospitals, federally qualified health centers, academic medical centers, and national providers: University of Iowa Health Care, Denver Health, CVS Health, Children's Hospital Los Angeles, and Carle Health. Over the past year, adoption has surged across ambulatory, behavioral health, pediatric, and emergency settings, with early expansion into inpatient and nursing workflows underway. The assistant operates in 35 languages, a factor the company cites as critical for safety-net and pediatric environments where clinician time is stretched thin.

Health-system contracts illustrate the depth of integration. Children's Hospital Los Angeles moved from a 30-physician pediatric specialist pilot in March 2024 to a full specialist rollout after the pilot demonstrated measurable documentation-time savings. Carle Health, an Illinois-based system, completed a four-week pilot across family medicine, pediatrics, cardiology, and other practice areas in mid-2024; over half of participating clinicians reported saving at least one hour per day on documentation. Dr. David Lovinger, Carle's associate chief medical officer and chief informatics officer, said the tool fit seamlessly into existing workflows and that onboarding support produced immediate results. At University of Iowa Health Care, Dr. James Blum, chief health information officer and associate professor of anesthesiology, described adoption speed as unprecedented for an academic medical center serving a wide range of clinical needs. Peer-reviewed studies from University of Iowa and real-world data from Denver Health confirm significant reductions in burnout and a 15-point increase in patient satisfaction scores. The American Hospital Association's April 2026 report highlighted six systems — including Cleveland Clinic and Cooper University Healthcare — reporting measurable improvements in care delivery and clinician satisfaction through ambient AI scribe deployment, signaling broader market validation.

Epic integration represents Nabla's deepest technical moat. On October 7, 2025, the company announced its addition to Epic Toolbox for Ambient Voice Recognition, a designation that embeds Nabla directly inside Epic's native workflow rather than relying on overlay or API-only approaches. The move coincides with Epic's expansion of embedded-tool APIs for orders, flowsheets, and inpatient workflows. Nabla also integrates with Cerner, athenahealth, NextGen, Greenway, and more than 20 other EHRs, but the Epic Toolbox placement is the strongest signal of enterprise-grade interoperability. Carle Health's rollout was explicitly executed through Epic integration, and the company's press materials describe its Epic integration as best in class.

On the reimbursement front, the 2026 Medicare cycle introduces new documentation guidelines for AI-generated notes, including CMS authentication rules and compliance requirements for billing. Nabla's roadmap includes a Proactive Coding Agent designed to guide E/M coding and surface compliance nudges, a direct response to the evolving reimbursement landscape. While Medicare has not yet established a distinct payment code for ambient AI scribing, the 2026 guidelines create a compliance framework that vendors and health systems must navigate, and Nabla's coding-agent investment signals it intends to turn compliance into a competitive advantage.

Rivals React: Migration Guides and Billion-Dollar Wars

Microsoft's Nuance division has responded to Nabla's Series C with the most direct competitive maneuver in the market: a dedicated migration program targeting Nabla's installed base. The DAX Copilot comparison site now features the migration guide, "White Glove Migration Support" promising zero downtime and full data preservation, and "special migration incentives available for Nabla users." Nuance is leveraging its structural advantage (DAX Copilot runs natively inside Epic's Haiku mobile app, while Nabla users must launch encounters from desktop to trigger a phone push notification) and turning it into a switching-cost argument. RCT data backs the usability claim: DAX was used in 33.5 percent of roughly 24,700 visits versus Nabla's 29.5 percent of roughly 23,700 visits, though neither tool cracked 35 percent adoption even when provided free during the trial.

Nuance's health-system reference customers read like a rebuttal to Nabla's efficiency narrative. Northwestern Medicine reports 112 percent ROI in year one, five additional appointments per month, and 92 percent of physicians finding DAX easier to use. University of Michigan Health cites 12 additional visits monthly, 20 more work RVUs, and 80 percent ROI from volume gains. WellSpan Health claims 94 percent improved patient interactions, nine additional patients monthly, and 88 percent better work-life balance. None of these figures are independently audited; all come from Nuance's own comparison site. But they signal how Microsoft is framing the value proposition: not documentation time savings — the RCT showed DAX produced no statistically significant reduction in time-in-note versus control (−1.7%, P=0.66) — but downstream revenue and retention metrics that CFOs and CMOs actually track.

Abridge's countermove is capital intensity and platform expansion. The company closed a $300 million Series E in 2025 at a $5.3 billion valuation, dwarfing Nabla's $70 million Series C and bringing total funding well past $400 million. Sacra estimates Abridge hit $100 million ARR in May 2025, up from $60 million at year-end 2024, with contracted ARR reaching $117 million in Q1 2025. That revenue trajectory, nearly doubling in five months, reflects enterprise deployments across major health systems rather than pilot conversions. Abridge's CTO has explicitly stated the company is rebranding as "more than an AI scribe," and the product moves bear that out: a partnership with NVIDIA for model infrastructure, and a collaboration with Eli Lilly extending into clinical trial documentation. Abridge is building horizontally across the clinical workflow while Nabla doubles down on the physician encounter.

Notable Health, the third pure-play vendor named in 2026 comparison guides alongside DAX, Abridge, Nabla, DeepScribe, Suki, and Freed, shows quieter momentum. The most recent Notable openings are a VP of Revenue Operations and senior AI infrastructure engineers in Redwood City, suggesting a go-to-market push backed by technical hardening rather than product breadth.

Looming over all three pure plays is a fourth competitive tier: the EHR vendors themselves. Epic, Oracle Health, and Meditech all shipped native ambient AI documentation capabilities in 2024–2025. Epic's Toolbox inclusion of Nabla is a partnership, not an acquisition, but Epic's own ambient features, Oracle Health's AI-powered patient portal, and Meditech's embedded scribe reduce the addressable market for standalone tools. Health systems evaluating Nabla, DAX, or Abridge now have a "build vs. buy" option that didn't exist two years ago: turn on the EHR's native module, avoid a vendor contract, and accept feature gaps the vendor will close on the EHR's roadmap.

The category is collapsing toward agentic documentation: transcription, CDI, and point-of-care coding merging into a single vertical, as Ambience Healthcare's $243 million Series C and nearly $1 billion in 2025 ambient AI funding illustrate. Nabla's agentic AI pitch, Abridge's "more than a scribe" rebrand, and Nuance's migration offensive are all bids to own the layer above the EHR before the EHR vendors absorb it. The RCT's central finding, that product choice matters and health systems should not assume ambient AI tools are interchangeable, is the only independent evidence in a market now driven by migration incentives, revenue claims, and platform ambition.

How Big Is This Market — And What's Not Nabla

Market forecasts for ambient clinical intelligence vary widely depending on who's counting and what they count.

The spread reflects different definitions: some include only software platforms, others fold in services, hardware, and adjacent analytics. What's consistent: North America owns roughly 45 percent of revenue today, hospitals are the primary buyer, and clinical documentation remains the dominant use case at nearly half of all spending.

Nabla's disclosed footprint puts it in the top tier of pure-play vendors, but well behind Nuance. Microsoft's DAX Copilot runs in 550-plus health systems. Abridge, after its $300 million Series E, has not published a clinician count but signals scale through Epic partnerships and a push into nursing documentation. Nabla's Epic Toolbox inclusion and Carle Health rollout show enterprise traction, yet the company has not released a market-share estimate. With total funding now at $120 million against Abridge's $400 million-plus and Microsoft's effectively unlimited balance sheet, Nabla's share will likely remain in the single digits globally for the foreseeable future. The U.S. addressable portion ($2.9 billion in 2025 per SNS Insider) suggests a realistic ceiling of $100–200 million ARR for a pure-play vendor at current pricing, assuming 5–7 percent penetration.

Three structural challenges bracket every vendor's growth. First, data privacy and HIPAA compliance: any high-profile breach involving ambient audio or generated notes would trigger regulatory retrenchment across the sector. Second, accuracy in noisy, multi-speaker environments (emergency departments, rounding teams, family conferences) remains a technical ceiling that limits deployment in high-acuity settings. Third, clinician change management: adoption rates above 85 percent require dedicated change-management protocols, and trust deficits persist around AI-generated notes that clinicians must still review and sign. Integration friction with Epic, Cerner, and athenahealth adds cost and delay, especially for smaller practices without IT bandwidth. Regulatory uncertainty around liability for AI-generated documentation errors (who owns a missed diagnosis embedded in an auto-generated note) could prompt restrictive rules in key markets.

Competitive intensity is rising. Microsoft expanded DAX deployment across major U.S. systems in February 2025, then announced a $1.3 billion DAX expansion in February 2026 to add care-gap identification and predictive risk scoring. AWS enhanced Transcribe Medical and HealthLake in January 2025. Oracle, athenahealth, and eClinicalWorks are embedding agentic AI into their platforms. Pure-play vendors face pricing pressure and consolidation risk.

Nuance's migration guide offers a clear path to the status quo. Nabla's Series C buys a bet that the next era belongs to agents that don't just listen — they act. The RCT says the choice matters. Health systems now decide whether to migrate to the past or build toward the 1% done.

Working in frontier tech? Zero G Talent tracks the openings: see every open Abridge role, browse frontier tech jobs, openings at Ambient and Nabla Bio, and the people building the field.